Skip to main content
. 2015 Sep;3(15):207. doi: 10.3978/j.issn.2305-5839.2015.05.13

Table 3. Long-term follow-up data with BRAF inhibitors.

Agents OS rate (%)
BRIM-1 study 6 months: 87.3; 1 year: 55.0; 2 years: 35.6; 3 years: 25.9
BRIM-3 study 1 year: 56
BREAK-2 study 18.8 months V600K: 25; 30 months V600E: 28
BREAK-3 study 2 years: 45

OS, overall survival.